Insuman Comb 30 Solostar

Insulin Human, the active ingredient in Insuman Comb 30 Solostar, is an insulin presented as a premixed injectable solution for subcutaneous use. It lowers blood glucose in patients with diabetes mellitus, both type 1 and type 2, by providing basal and prandial insulin coverage. GNH USA supplies Insuman Comb 30 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 30 Solostar is an insulin preparation indicated for the management of diabetes mellitus, acting on glucose metabolism to achieve glycaemic control.

- Type 1 diabetes mellitus: provides both basal and rapid‑acting insulin to mimic physiological insulin secretion and maintain target blood glucose levels. - Type 2 diabetes mellitus: supplements endogenous insulin, helping patients achieve fasting and post‑prandial glucose targets when oral agents are insufficient. - Intensive insulin therapy: used in regimens that require a fixed proportion of intermediate‑acting and short‑acting insulin to simplify dosing schedules.

Insuman Comb 30 Solostar may cause a range of adverse reactions. Patients should be aware of both frequent and infrequent events.

Common Side Effects: - Hypoglycaemia: episodes of low blood glucose, often presenting with sweating, tremor, or confusion. - Injection‑site reactions: redness, swelling, or itching at the site of administration. - Weight gain: gradual increase in body weight associated with improved glycaemic control. - Edema: mild peripheral swelling, particularly in the lower extremities. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness, seizures, or coma. - Allergic reactions: including urticaria, angioedema, or anaphylaxis requiring immediate medical attention. - Insulin antibodies: formation of antibodies that may alter insulin action or cause hypersensitivity. - Acute respiratory distress: rare cases of pulmonary edema. - Necrotising fasciitis: extremely rare but serious soft‑tissue infection at injection site.

When prescribing or using Insuman Comb 30 Solostar, several safety considerations are recommended. - Dose adjustment: individualize dosing based on frequent blood glucose monitoring and patient response. - Hypoglycaemia risk: educate patients on recognizing symptoms and managing low glucose episodes. - Renal impairment: monitor kidney function and adjust dose as needed. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications that may potentiate or mask hypoglycaemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 30 Solostar can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: may blunt typical hypoglycaemia warning signs, complicating detection. - Monoamine oxidase inhibitors (MAOIs): can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk. - Concurrent use of other insulins: may lead to insulin overdose and severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas): additive glucose‑lowering effect, requiring dose adjustments. - Thiazolidinediones: may alter insulin sensitivity, influencing overall glucose control. - ACE inhibitors or ARBs: can enhance insulin’s effect on glucose uptake, necessitating careful monitoring.